Background {#Sec1}
==========

Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor are the first specific treatment for the prevention of episodic (EM) or chronic migraine (CM). The use of those drugs has raised great expectations \[[@CR1]\], and their efficacy and excellent safety make them suitable for most migraineurs. However, due to their high cost, patient selection is an important issue \[[@CR2], [@CR3]\]. It has been suggested that their use may be firstly considered for those with disabling attacks or for those in the pre-chronic stage of the disease to prevent CM \[[@CR4], [@CR5]\]. The *American Headache Society* \[[@CR6]\] and the *European Headache Federation* \[[@CR7]\] currently recommend monoclonal antibodies acting on the CGRP or its receptor in patients who failed at least two of the available preventive treatments.

Erenumab, a fully human monoclonal antibody directed against the CGRP receptor, was approved for the prevention of EM or CM at the monthly dose of 70 or 140 mg; the 70 mg monthly dose is recommended in most patients with migraine, while the 140 mg dose provides an additional benefit to some patients \[[@CR8]\]. We performed a critical appraisal of the available literature to understand if patients who had failed prior preventive treatments may benefit more from the 140 mg erenumab dose than the 70 mg.

Methods {#Sec2}
=======

We searched papers indexed in PubMed over the last 2 years which contained the terms 'migraine' and 'erenumab' in their title or abstract. We also manually searched conference abstracts published over the same time span. Papers and abstracts were eligible for this review if they reported about the effect of erenumab in patients with and without prior preventive treatment failures.

Review of the available trials {#Sec3}
==============================

Detailed information on patients with prior preventive treatment failures was available from 3 randomized controlled trials (RCTs) -- the NCT02066415, the Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (STRIVE), and the 12-week Double-blind, Randomized, Multicenter Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients Who Have Failed Prophylactic Migraine Treatments (LIBERTY) (Table [1](#Tab1){ref-type="table"}) \[[@CR9], [@CR14], [@CR17]\] - and their subgroup analyses or open-label extensions (OLEs) \[[@CR10]--[@CR13], [@CR15], [@CR16], [@CR18], [@CR19]\]. Table 1Characteristics of the randomized controlled trials assessing the effect of prior preventive treatment failures on the treatment with erenumab for migraine preventionNCT02066415\
\[[@CR9]--[@CR13]\]STRIVE\
\[[@CR14]--[@CR16]\]LIBERTY\
\[[@CR17], [@CR18]\]PhaseIIIIIIIIbMigraine typeCMEMEMDose (mg)70/14070/140140OLE duration (weeks)525224Duration of blind phase (weeks)122412Prior preventive treatment failures^a^ accepted≤3≤22--4No. of patients Placebo286319125 70 mg191317-- 140 mg190319121Patients with prior preventive treatment failure(s) (%) Placebo7040100 70 mg6740-- 140 mg6636100*MMD* Monthly Migraine Days, *OLE* Open-Label Extension, *EM* Episodic Migraine, *CM* Chronic Migraine^a^due to lack of response; partial response or suspension due to tolerability were accepted

The STRIVE trial considered 7 categories of preventive treatments, namely: 1) divalproex sodium, sodium valproate; 2) topiramate; 3) beta blockers; 4) tricyclic antidepressants; 5) serotonin-norepinephrine reuptake inhibitors; 6) flunarizine, verapamil; and 7) lisinopril, candesartan \[[@CR14]\]; the NCT02066415 trial considered the same categories plus botulinum toxin \[[@CR9]\], while the LIBERTY trial included in migraine prophylaxis treatments propranolol/metoprolol, topiramate, flunarizine, valproate/divalproex, amitriptyline, venlafaxine, lisinopril, candesartan, and locally approved products (e.g. oxeterone or pizotifen) \[[@CR17]\].

Episodic migraine {#Sec4}
-----------------

In the STRIVE trial \[[@CR14]\], information on patients with prior preventive treatment failures came from subgroup analyses \[[@CR15]\]. In that study, patients who failed more than ≥2 preventive drug categories were excluded, while the LIBERTY study included only patients with 2 to 4 prior treatment failures \[[@CR17]\].

In the STRIVE trial, both the 70 and the 140 mg doses of erenumab performed significantly better than placebo in patients in whom ≥1 and ≥ 2 preventive treatment categories had failed (Fig. [1](#Fig1){ref-type="fig"}). The advantages of erenumab over placebo increased with the increase in the number of preventive treatment failures due to the decrease in the placebo effect. Notably, the effect of the 140 mg dose remained stable independent of the number of prior preventive treatment failures while the effect of the 70 mg decreased with the increasing number of failures (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR15]\]. The preliminary data of the OLE of the same trial (Fig. [1](#Fig1){ref-type="fig"}) showed that, in patients with ≥1 prior preventive treatment failure(s), the numerical advantage of the 140 mg over the 70 mg monthly dose in terms of monthly migraine days and acute medication days was sustained until week 52 \[[@CR16]\]. Fig. 1Patients with episodic migraine: effect of erenumab on monthly migraine days, monthly migraine-specific medication days, and 50% reduction in monthly migraine days from baseline according to prior preventive treatment failures in the STRIVE trial \[[@CR15]\] and its open-label extension \[[@CR16]\]

In the LIBERTY trial, the 140 mg monthly dose of erenumab significantly increased the proportion of EM patients experiencing a ≥ 50% reduction in monthly migraine days compared with placebo (30% vs 17%) \[[@CR17]\], and the preliminary OLE data showed that the effect was sustained over 24 weeks \[[@CR18]\].

Chronic migraine {#Sec5}
----------------

In the 12-week NCT02066415 trial \[[@CR9]\], patients were treated with erenumab 70 or 140 mg; information on patients with prior preventive treatment failures came from prespecified subgroup analyses \[[@CR10]\]; in this study patients who failed more than 2 preventive drug categories were excluded.

Even in CM patients, both doses of erenumab were significantly better than placebo in the subgroup of subjects with ≥1 and ≥ 2 preventive treatment category failures. Again, the advantage of erenumab over placebo increased with the increase in the number of preventive treatment failures due to decreasing placebo effect (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR10]\]. In the case of CM, even in the absence of direct comparisons, the 140 mg dose appeared numerically more advantageous than the 70 mg dose but there was not decreasing efficacy of the 70 mg dose with increasing number of treatment failures. Additionally, the CM-to-EM conversion rates over 12 weeks were similar with erenumab 70 mg or 140 mg compared with placebo (52.4% and 52.0% vs 28.9%) in CM patients with ≥1 prior preventive treatment failure(s) \[[@CR19]\]. Fig. 2Patients with chronic migraine: effect of erenumab on monthly migraine days, monthly migraine-specific medication days, and 50% reduction in monthly migraine days from baseline according to prior preventive treatment failures in the NCT02066415 trial \[[@CR10]\] and its open-label extension \[[@CR11]\]

A long-term analysis of the trial OLE showed that patients with ≥1 prior preventive treatment failure(s) benefited from a sustained numerical advantage of the 140 mg monthly dose over the 70 mg one at Week 52 (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR11]\].

A subgroup analysis of the NCT02066415 trial showed a comparable efficacy of the 70 mg and 140 mg monthly doses in patients with CM and medication overuse \[[@CR12]\]; however, in those with ≥1 prior preventive treatment failure(s) the 140 mg monthly dose conferred an advantage over the 70 mg dose \[[@CR13]\] (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Patients with chronic migraine and medication overuse: effect of erenumab on monthly migraine days, monthly migraine-specific medication days, and 50% reduction in monthly migraine days from baseline according to prior preventive treatment failures in the NCT02066415 trial \[[@CR12], [@CR13]\]

Discussion {#Sec6}
==========

There are no data directly comparing the efficacy of the 70 and 140 mg erenumab dosing nor randomized dose-escalation studies. However, raw numbers suggest a slight clinical advantage of the 140 mg monthly dose of erenumab over the 70 mg monthly dose, which is more evident with increasing prior preventive treatment failures and in subjects with EM \[[@CR10], [@CR15]\]. This may suggest that treatment, in patients with prior preventive failures should be started or soon increased to the 140 mg dose. This treatment strategy will be feasible without additional costs or patient discomfort, since erenumab will be commercially available also in a single 140 mg injection \[[@CR8]\]. Besides, no dose-related side effects were reported from the RCTs and their OLEs \[[@CR9], [@CR10], [@CR14], [@CR15], [@CR20]\]. It is important to note that the LIBERTY trial included patients with EM with inadequate response, insufficient dosage or adverse events to 2--4 prior preventive treatments, and that this trial examined the 140 mg dose \[[@CR17]\].

In the clinical practice setting erenumab is offered to patients not responding to multiple prior preventive treatments or unable to tolerate them because of lack of efficacy. Indeed, the *European Headache Federation* guidelines \[[@CR7]\] and the position statement of the *American Headache Society* \[[@CR6]\] recommend the use of monoclonal antibodies acting on the CGRP or its receptor in patients who failed ≥2 available preventive treatments because of lack of efficacy and/or poor tolerability, in order to limit the use of the costly novel migraine preventive treatments to the patients who need them most. Therefore, the profile of the patients who will be treated in the daily clinical practice will mainly match that of the LIBERTY study, which used the 140 mg dose only. Notably, the numerical advantage of the 140 mg dose over the 70 mg among patients with CM and prior preventive treatment failure(s) was independent of the presence of medication overuse \[[@CR12], [@CR13]\].

The selection of the right dose of erenumab for the right patient is still an open issue. It is important to act rapidly and effectively on the symptoms and on the progression of migraine and its associated disability. In RCTs, a relevant proportion of treatment failures was attributable to an insufficient dosage or to adverse events, rather than to a lack of response; besides, all RCTs except LIBERTY included a proportion of patients taking erenumab as their first preventive treatment (Table [1](#Tab1){ref-type="table"}). We have no information on response to treatment for patients who failed previous preventatives versus those who did not tolerate them. Those who failed may represent a more difficult to treat subgroup as compared to those who did not tolerate treatment. Further data are also needed to assess whether the response to different erenumab doses of CM is different from that of EM. More data are also needed to assess whether the benefit of the 140 mg dose over the 70 mg one in patients with multiple prior preventive treatment failures is sustained over time; however, the available preliminary data regarding patients with ≥1 prior treatment failure(s) suggest a prolonged benefit \[[@CR11], [@CR16]\]. Notably, there are no data to indicate dose switch from 70 mg to 140 mg monthly, since in the available RCTs patients started and continued treatment with one of the two doses. Only some patients enrolled in the NCT02066415 trial switched doses 4 to 28 weeks after the double blind phase \[[@CR11]\], and no analyses are available for that subgroup.

Conclusions {#Sec7}
===========

According to the available data, the 140 mg monthly dose of erenumab should be preferred over the 70 mg dose in patients with migraine and prior preventive treatment failures, which is the target population according to available guidelines for prevention of migraine with monoclonal antibodies acting on the CGRP or its receptor. Further open-label and real-world studies will address the long-term benefit of starting -- or switching to -- the treatment with high-dose erenumab.
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